Reusable optofluidic point-of-care testing platform with lyophilized specific antibody for fluorescence detection of cholylglycine in serum

• Published in: Mikrochimica acta (1966) Vol. 187; no. 8; p. 439
• Main Authors: Liu, Jiayao, Xu, Wenjuan, Zhu, Anna, Kang, Haoxiang, Cao, Yu, Long, Feng
• Format: Journal Article
• Language: English
• Published: Vienna Springer Vienna 01.08.2020; Springer; Springer Nature B.V
• Subjects: Analytical Chemistry; Antibodies; Biomarkers; Biosensors; Characterization and Evaluation of Materials; Chemical tests and reagents; Chemistry; Chemistry and Materials Science; Detectors; Diagnostic systems; Dilution; Equipment and supplies; Evanescent waves; Fiber optics; Fluorescence; Immunoassay; Microengineering; Nanochemistry; Nanotechnology; Optical fibers; Original Paper; Point of care testing; Reagents; Sensitivity; Transmission efficiency; Viral antibodies; Evanescent wave fluorescence; Point-of-testing; Immunoassay; Optofluidic; Cholylglycine
• DOI: 10.1007/s00604-020-04424-2
• ISSN: 0026-3672; 1436-5073

A reusable optofluidic point-of-care testing platform (OPOCT) was successfully constructed through integrating evanescent wave fluorescence technology into an all-fiber-based optofluidic system. The compact design of the OPOCT allows it to be portable and suitable for on-site sensitive determination of biomarkers in serum without complicated and costly procedures. The sensitivity of 90.9 pM for antibody determination is observed thanks to the high transmission efficiency of excitation light and fluorescence in the OPOCT. The affinity constant between cholylglycine (CG) and anti-CG antibody was quantified using this platform based on the proposed theory. Using the lyophilized fluorescence-labeled specific antibody and reusable fiber optic biosensor, the OPOCT is applied to the one-step sensitive determination of CG in serum, which eliminates the dearth associated with liquid reagent handling, disposable biosensors, and user intervention. A limit of detection of 0.025 μg/mL for CG is obtained, which is far more than adequate for meeting diagnostic requirements. The matrix effect of serum samples on the evanescent wave–based optofluidic biosensor can be effectively reduced by simple dilution of serum samples. The performance of the OPOCT also compared favorably with that of a commercial turbidimetric inhibition immunoassay through analyzing multiple serum samples. This platform is ready to expand to measure any other biomarker by using its specific antibody. The simplicity, sensitivity, cost-effectiveness, and robustness of the OPOCT enable the early diagnosis of disease and making a timely clinical decision. Graphical abstract .